Details

Autor(en) / Beteiligte

• Wong, R P
• Baetz, T
• Krahn, M J
• Biagi, J
• Wainman, N
• Eisenhauer, E

Titel

SarCNU in recurrent or metastatic colorectal cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

Ist Teil von

• Investigational new drugs, 2006-07, Vol.24 (4), p.347-351

Ort / Verlag

United States: Springer Nature B.V

Erscheinungsjahr

2006

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate the activity and toxicity of SarCNU, an oral chloroethylnitrosourea in patients with recurrent or metastatic colorectal cancer who have progressed after first-line chemotherapy. Eighteen patients with recurrent or metastatic colorectal cancer following first-line chemotherapy were treated with SarCNU 860 mg/m2 orally day 1, 5 and 9 every 6 weeks. The patient's median age was 64 and the ECOG performance status was 0 in six, 1 in eleven and 2 in one patients. All patients were evaluable for toxicity and 16 were evaluable for response. There were no objective responses (0%). One patient had stable disease and 15 had progressive disease at their first follow-up assessment. Median survival was 7.36 months (3.75-7.49 95% C.I.). Neutropenia and thrombocytopenia were the most severe toxicities (grade 3-4 in six and nine patients respectively). Pulmonary toxicity was also seen in five patients who had a drop of DLCO grade from baseline and two patients who had a fall in FVC from baseline. SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.